MURIELLE VÉNIANT-ELLISON
Scientific Vice President of Research,
Cardiometabolic Disorders
Amgen
Murielle Véniant-Ellison heads a group in Amgen’s Department of Cardiometabolic Disorders, Discovery Research, with a focus on early-stage drug development for obesity and heart failure indications. She previously played a central role in developing Amgen’s diabetes program. Since 2000, Véniant-Ellison has been a key member in the Cardiometabolic Disorders leadership team and has guided large and small molecule candidates from basic research to Phase 1 clinical trials.
Véniant-Ellison’s interest in science originated from her childhood experiences in a small village in France. She earned a Ph.D. in Pharmacology from the University of Dijon. Following a post-doctoral fellowship and research, Véniant-Ellison joined Amgen in 2000. Her team focused on discovering effective weight loss molecules, leading to potential therapies for obesity in Amgen’s clinical pipeline. In 2021, Véniant-Ellison, made history as the first industry-based scientist to give the Havel Lecture at the Deuel Conference on Lipids, an esteemed event in lipid research.
